RAF1 and familial pancreatic carcinoma: As researchers explore the dynamic space of targeted therapy combinations in pancreatic cancer, the optimism of the recent advancements is tempered by the potential for overlapping toxicities in regimens incorporating two inhibitors targeting within the RAF/MEK/ERK pathway or combined with other targets, like in the case of dual inhibition with afatinib and trametinib [74].